

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING**1.1. Product identifier**

Product Description: Erlotinib hydrochloride
Cat No. : 462330000; 462330010; 462330050
CAS No 183319-69-9
Molecular Formula C22 H24 Cl N3 O4

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Laboratory chemicals.
Uses advised against No Information available

1.3. Details of the supplier of the safety data sheet**Company**

UK entity/business name
Fisher Scientific UK
Bishop Meadow Road,
Loughborough, Leicestershire LE11 5RG, United Kingdom

EU entity/business name
Thermo Fisher Scientific
Janssen Pharmaceuticalaan 3a, 2440 Geel, Belgium

E-mail address begel.sdsdesk@thermofisher.com

1.4. Emergency telephone number

For information **US** call: 001-800-227-6701 / **Europe** call: +32 14 57 52 11
Emergency Number **US**:001-201-796-7100 / **Europe**: +32 14 57 52 99
CHEMTREC Tel. No. **US**:001-800-424-9300 / **Europe**:001-703-527-3887

SECTION 2: HAZARDS IDENTIFICATION**2.1. Classification of the substance or mixture****CLP Classification - According to GB-CLP Regulations UK SI 2019/720 and UK SI 2020/1567****Physical hazards**

Based on available data, the classification criteria are not met

Health hazards

Acute oral toxicity

Category 4 (H302)

SAFETY DATA SHEET

Erlotinib hydrochloride

Revision Date 06-Oct-2023

Environmental hazards

Based on available data, the classification criteria are not met

Full text of Hazard Statements: see section 16

2.2. Label elements



Signal Word

Warning

Hazard Statements

H302 - Harmful if swallowed

Precautionary Statements

P301 + P330 + P331 - IF SWALLOWED: rinse mouth. Do NOT induce vomiting

P312 - Call a POISON CENTER or doctor if you feel unwell

P264 - Wash face, hands and any exposed skin thoroughly after handling

2.3. Other hazards

This product does not contain any known or suspected endocrine disruptors

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1. Substances

Component	CAS No	EC No	Weight %	CLP Classification - According to GB-CLP Regulations UK SI 2019/720 and UK SI 2020/1567
Erlotinib hydrochloride	183319-69-9		>95	Acute Tox. 4 (H302)

Full text of Hazard Statements: see section 16

SECTION 4: FIRST AID MEASURES

4.1. Description of first aid measures

General Advice If symptoms persist, call a physician.

Eye Contact Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Get medical attention.

Skin Contact Wash off immediately with plenty of water for at least 15 minutes. If skin irritation persists,

SAFETY DATA SHEET

Erlotinib hydrochloride

Revision Date 06-Oct-2023

call a physician.

Ingestion Clean mouth with water and drink afterwards plenty of water. Get medical attention if symptoms occur.

Inhalation Remove to fresh air. If not breathing, give artificial respiration. Get medical attention if symptoms occur.

Self-Protection of the First Aider Ensure that medical personnel are aware of the material(s) involved, take precautions to protect themselves and prevent spread of contamination.

4.2. Most important symptoms and effects, both acute and delayed

None reasonably foreseeable.

4.3. Indication of any immediate medical attention and special treatment needed

Notes to Physician Treat symptomatically.

SECTION 5: FIREFIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media

Water spray, carbon dioxide (CO₂), dry chemical, alcohol-resistant foam.

Extinguishing media which must not be used for safety reasons

No information available.

5.2. Special hazards arising from the substance or mixture

Thermal decomposition can lead to release of irritating gases and vapors.

Hazardous Combustion Products

Carbon monoxide (CO), Carbon dioxide (CO₂), Nitrogen oxides (NO_x), Hydrogen chloride.

5.3. Advice for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Ensure adequate ventilation. Use personal protective equipment as required. Avoid dust formation.

6.2. Environmental precautions

Should not be released into the environment.

6.3. Methods and material for containment and cleaning up

Sweep up and shovel into suitable containers for disposal. Keep in suitable, closed containers for disposal.

6.4. Reference to other sections

Refer to protective measures listed in Sections 8 and 13.

SAFETY DATA SHEET

Erlotinib hydrochloride

Revision Date 06-Oct-2023

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Wear personal protective equipment/face protection. Ensure adequate ventilation. Do not get in eyes, on skin, or on clothing. Avoid ingestion and inhalation. Avoid dust formation.

Hygiene Measures

Handle in accordance with good industrial hygiene and safety practice. Keep away from food, drink and animal feeding stuffs. Do not eat, drink or smoke when using this product. Remove and wash contaminated clothing and gloves, including the inside, before re-use. Wash hands before breaks and after work.

7.2. Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Technical Rules for Hazardous Substances (TRGS) 510 Class 11
Storage Class (LGK) (Germany)

7.3. Specific end use(s)

Use in laboratories

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure limits

This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies

Biological limit values

This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies

Derived No Effect Level (DNEL) / Derived Minimum Effect Level (DMEL)

No information available

Predicted No Effect Concentration (PNEC)

No information available.

8.2. Exposure controls

Engineering Measures

Ensure adequate ventilation, especially in confined areas.

Wherever possible, engineering control measures such as the isolation or enclosure of the process, the introduction of process or

SAFETY DATA SHEET

Erlotinib hydrochloride

Revision Date 06-Oct-2023

equipment changes to minimise release or contact, and the use of properly designed ventilation systems, should be adopted to control hazardous materials at source

Personal protective equipment

Eye Protection

Wear safety glasses with side shields (or goggles) (European standard - EN 166)

Hand Protection

Protective gloves

Glove material	Breakthrough time	Glove thickness	EU standard	Glove comments (minimum requirement)
Nitrile rubber	See manufacturers recommendations	-	EN 374	
Neoprene				
Natural rubber				
PVC				

Skin and body protection

Long sleeved clothing.

Inspect gloves before use.

Please observe the instructions regarding permeability and breakthrough time which are provided by the supplier of the gloves.
(Refer to manufacturer/supplier for information)

Ensure gloves are suitable for the task: Chemical compatibility, Dexterity, Operational conditions, User susceptibility, e.g. sensitisation effects, also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion.

Remove gloves with care avoiding skin contamination.

Respiratory Protection

When workers are facing concentrations above the exposure limit they must use appropriate certified respirators.

To protect the wearer, respiratory protective equipment must be the correct fit and be used and maintained properly

Large scale/emergency use

Use a NIOSH/MSHA or European Standard EN 136 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced

Recommended Filter type: Particulates filter conforming to EN 143

Small scale/Laboratory use

Use a NIOSH/MSHA or European Standard EN 149:2001 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Recommended half mask:- Particle filtering: EN149:2001
When RPE is used a face piece Fit Test should be conducted

Environmental exposure controls

No information available.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical State

Solid

Appearance

White

Odor

No information available

Odor Threshold

No data available

Melting Point/Range

215 - 227 °C / 419 - 440.6 °F

Softening Point

No data available

Boiling Point/Range

No information available

Flammability (liquid)

Not applicable

Solid

Flammability (solid,gas)

No information available

Explosion Limits

No data available

Flash Point

No information available

Method - No information available

Autoignition Temperature

No data available

Decomposition Temperature

No data available

pH

No information available

Viscosity

Not applicable

Solid

Water Solubility

Slightly soluble

SAFETY DATA SHEET

Erlotinib hydrochloride

Revision Date 06-Oct-2023

Solubility in other solvents	No information available
Partition Coefficient (n-octanol/water)	
Component	log Pow
Erlotinib hydrochloride	4.878
Vapor Pressure	No data available
Density / Specific Gravity	No data available
Bulk Density	No data available
Vapor Density	Not applicable
Particle characteristics	Solid No data available

9.2. Other information

Molecular Formula	C22 H24 Cl N3 O4
Molecular Weight	429.90
Evaporation Rate	Not applicable - Solid

SECTION 10: STABILITY AND REACTIVITY

10.1. Reactivity

None known, based on information available

10.2. Chemical stability

No information available.

10.3. Possibility of hazardous reactions

Hazardous Polymerization	No information available.
Hazardous Reactions	None under normal processing.

10.4. Conditions to avoid

Incompatible products.

10.5. Incompatible materials

Strong oxidizing agents. Strong acids.

10.6. Hazardous decomposition products

Carbon monoxide (CO). Carbon dioxide (CO₂). Nitrogen oxides (NO_x). Hydrogen chloride.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Product Information	Harmful if swallowed
----------------------------	----------------------

(a) acute toxicity;

Oral	Category 4
Dermal	No data available
Inhalation	No data available

(b) skin corrosion/irritation;	No data available
---------------------------------------	-------------------

(c) serious eye damage/irritation;	No data available
---	-------------------

SAFETY DATA SHEET

Erlotinib hydrochloride

Revision Date 06-Oct-2023

(d) respiratory or skin sensitization;

Respiratory No data available
Skin No data available

(e) germ cell mutagenicity;

No data available

(f) carcinogenicity;

No data available

There are no known carcinogenic chemicals in this product

(g) reproductive toxicity;

No data available

(h) STOT-single exposure;

No data available

(i) STOT-repeated exposure;

No data available

Target Organs No information available.

(j) aspiration hazard;

Not applicable
Solid

Other Adverse Effects

The toxicological properties have not been fully investigated.

Symptoms / effects, both acute and delayed No information available.

11.2. Information on other hazards

Endocrine Disrupting Properties

Assess endocrine disrupting properties for human health. This product does not contain any known or suspected endocrine disruptors.

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity

Ecotoxicity effects

Contains no substances known to be hazardous to the environment or that are not degradable in waste water treatment plants.

12.2. Persistence and degradability

Persistence

May persist, based on information available.

12.3. Bioaccumulative potential

May have some potential to bioaccumulate; Product has a high potential to bioconcentrate

Component	log Pow	Bioconcentration factor (BCF)
Erlotinib hydrochloride	4.878	No data available

12.4. Mobility in soil

Is not likely mobile in the environment due its low water solubility. Is not likely mobile in the environment due its low water solubility and propensity to bind to soil particles

12.5. Results of PBT and vPvB

No data available for assessment.

SAFETY DATA SHEET

Erlotinib hydrochloride

Revision Date 06-Oct-2023

assessment

12.6. Endocrine disrupting properties

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors

12.7. Other adverse effects

Persistent Organic Pollutant

Ozone Depletion Potential

This product does not contain any known or suspected substance

This product does not contain any known or suspected substance

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from Residues/Unused Products

Waste is classified as hazardous. Dispose of in accordance with the European Directives on waste and hazardous waste. Dispose of in accordance with local regulations.

Contaminated Packaging

Dispose of this container to hazardous or special waste collection point.

European Waste Catalogue (EWC)

According to the European Waste Catalog, Waste Codes are not product specific, but application specific.

Other Information

Waste codes should be assigned by the user based on the application for which the product was used. Do not empty into drains.

SECTION 14: TRANSPORT INFORMATION

IMDG/IMO

Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

ADR

Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

IATA

Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

14.5. Environmental hazards

No hazards identified

14.6. Special precautions for user

No special precautions required.

14.7. Maritime transport in bulk

Not applicable, packaged goods

SAFETY DATA SHEET

Erlotinib hydrochloride

Revision Date 06-Oct-2023

according to IMO instruments

SECTION 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

Europe (EINECS/ELINCS/NLP), China (IECSC), Taiwan (TCSI), Korea (KECL), Japan (ENCS), Japan (ISHL), Canada (DSL/NDSL), Australia (AICS), New Zealand (NZIoC), Philippines (PICCS). US EPA (TSCA) - Toxic Substances Control Act, (40 CFR Part 710)

Component	CAS No	EINECS	ELINCS	NLP	IECSC	TCSI	KECL	ENCS	ISHL
Erlotinib hydrochloride	183319-69-9	-	-	-	-	X	-	-	X

Component	CAS No	TSCA	TSCA Inventory notification - Active-Inactive	DSL	NDSL	AICS	NZIoC	PICCS
Erlotinib hydrochloride	183319-69-9	-	-	-	-	-	-	-

Legend: X - Listed '-' - Not Listed

KECL - NIER number or KE number (<http://ncis.nier.go.kr/en/main.do>)

Authorisation/Restrictions according to EU REACH

Not applicable

Component	CAS No	REACH (1907/2006) - Annex XIV - Substances Subject to Authorization	REACH (1907/2006) - Annex XVII - Restrictions on Certain Dangerous Substances	REACH Regulation (EC 1907/2006) article 59 - Candidate List of Substances of Very High Concern (SVHC)
Erlotinib hydrochloride	183319-69-9	-	-	-

Seveso III Directive (2012/18/EC)

Component	CAS No	Seveso III Directive (2012/18/EC) - Qualifying Quantities for Major Accident Notification	Seveso III Directive (2012/18/EC) - Qualifying Quantities for Safety Report Requirements
Erlotinib hydrochloride	183319-69-9	Not applicable	Not applicable

Regulation (EC) No 649/2012 of the European Parliament and of the Council of 4 July 2012 concerning the export and import of dangerous chemicals

Not applicable

Contains component(s) that meet a 'definition' of per & poly fluoroalkyl substance (PFAS)?

Not applicable

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work .

National Regulations

UK - Take note of Control of Substances Hazardous to Health Regulations (COSHH) 2002 and 2005 Amendment

WGK Classification Water endangering class = 3 (self classification)

SAFETY DATA SHEET

Erlotinib hydrochloride

Revision Date 06-Oct-2023

15.2. Chemical safety assessment

A Chemical Safety Assessment/Report (CSA/CSR) has not been conducted

SECTION 16: OTHER INFORMATION

Full text of H-Statements referred to under sections 2 and 3

H302 - Harmful if swallowed

Legend

CAS - Chemical Abstracts Service

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

PICCS - Philippines Inventory of Chemicals and Chemical Substances

ENCS - Japanese Existing and New Chemical Substances

IECSC - Chinese Inventory of Existing Chemical Substances

AICS - Australian Inventory of Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

NZIoC - New Zealand Inventory of Chemicals

WEL - Workplace Exposure Limit

TWA - Time Weighted Average

ACGIH - American Conference of Governmental Industrial Hygienists

IARC - International Agency for Research on Cancer Predicted No Effect Concentration (PNEC)

DNEL - Derived No Effect Level

LD50 - Lethal Dose 50%

RPE - Respiratory Protective Equipment

EC50 - Effective Concentration 50%

LC50 - Lethal Concentration 50%

POW - Partition coefficient Octanol:Water

NOEC - No Observed Effect Concentration

vPvB - very Persistent, very Bioaccumulative

PBT - Persistent, Bioaccumulative, Toxic

ADR - European Agreement Concerning the International Carriage of Dangerous Goods by Road

ICAO/IATA - International Civil Aviation Organization/International Air Transport Association

IMO/IMDG - International Maritime Organization/International Maritime Dangerous Goods Code

MARPOL - International Convention for the Prevention of Pollution from Ships

OECD - Organisation for Economic Co-operation and Development

ATE - Acute Toxicity Estimate

BCF - Bioconcentration factor

VOC - (Volatile Organic Compound)

Key literature references and sources for data

<https://echa.europa.eu/information-on-chemicals>

Suppliers safety data sheet, Chemadvisor - LOLI, Merck index, RTECS

Training Advice

Chemical hazard awareness training, incorporating labelling, Safety Data Sheets (SDS), Personal Protective Equipment (PPE) and hygiene.

Use of personal protective equipment, covering appropriate selection, compatibility, breakthrough thresholds, care, maintenance, fit and standards.

First aid for chemical exposure, including the use of eye wash and safety showers.

Creation Date 24-Oct-2016

Revision Date 06-Oct-2023

Revision Summary Not applicable.

This safety data sheet complies with Regulation UK SI 2019/758 and UK SI 2020/1577 as amended.

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage,

SAFETY DATA SHEET

Erlotinib hydrochloride

Revision Date 06-Oct-2023

transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text

End of Safety Data Sheet